ABOUT PFMD

About PFMD

About PFMD

 

By partnering with patients to design and develop new solutions, we can co-create methods for them to achieve their health goals.

To pave the path for new innovations in research and lifecycle of medicine development, we intend to improve the patient experience by prioritizing patient preferences and values and creating synergies across interventions which involve the voice of the patient.

We partner WITH patients.

The Issue

Medicines are developed to improve the lives of patients. By involving patients throughout the development process, drug trials can be designed to better reflect patient needs and accommodate the challenges they face. This can lead to improved participation rates in trials, help development of innovative medicines, allow more rapid access to new therapies, and improve health outcomes for patients.

Serving patients in the best way possible requires a deep understanding of their medical condition, which can be can be gained only through direct, sustained and constructive interactions with patients. Health stakeholders have converged on the idea that broadening patient engagement is key to improving drug development.

While stakeholders have started to develop guidelines and methodologies to improving patient engagement in medicines development, this is still in its infancy, and existing approaches are fragmented. An efficient, measurable and reliable framework that involves patients as partners has yet to be developed, validated and applied.

Our goal

The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed in collaboration with The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework.

PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility. Stakeholders include patients and patient organizations across diverse areas of health and industry. We also intend to invite regulators, payers and other professional organizations to the global group to ensure diversity of perspectives.

Remove the barriers to effective patient engagement

Find out how in our new paper – “Culture and process change as a priority for patient engagement in medicines development” – published in the peer-reviewed journal Therapeutic Innovation & Regulatory Science (TIRS)

Core Values

EMPATHY
TRANSPARENCY
CO-CREATION
GLOBAL IMPACT

Our approach to synergizing

  • Create standards throughout the lifecycle of medicine development that unify diverse stakeholders towards a common goal of improved health.
    Harmonization
  • Meaningful
    Engagement
    Align lifecycle of medicine development with patient needs and priorities across a global framework.
  • Foster innovation by identifying gaps, showcasing good practices and identifying new opportunities.
    Innovation
  • Information
    Exchange
    Facilitate sharing of information across healthcare through a learning exchange that promotes patient engagement.

PFMD Governance Model

  • Inclusive & Expert Advice
    Advisory Committee
    PFMD Member Organisations
    Patient representatives
    Pharma companies (committed to adopt the new framework)
    Academics
    Patient Advocates
    Funding and/or participating in kind
  • Agile & Driven Operations
    Management Group
    Experts
    Medical
    Legal
    Regulatory
    Patient Representatives
    Ethic
    Payer
    Communication
    Secretariat
    Communication
    Finance
    Advocacy
    Reporting & transparency
    Data Framework & Related Services

Partners

BECOME A PARTNER FOR PATIENT ENGAGEMENT...
Join PFMD